|
| |
| |
| |
|
Statistics |
| Unique Visitors: 2 |
| Total Unique Visitors: 9271 |
| Visitors Out: 296 |
| Total Visitors Out: 296 |
|
|
|
| |
|
|
| |
|
| Settlement with Ranbaxy extends patent of Lipitor |
| 2008-06-25 03:49:00 |
For Pfizer, the deal all but eliminates the possibility of generic competition for its flagship medicine before 2011, and allays recent concerns the company will not have the revenue and profit to maintain its coveted 32-cent-per-share quarterly dividend. Despite generic pressures, Pfizer has projected a 10 percent increase in its dividend this year.For Ranbaxy, which has aggressively challenged Lipitor's patents in courts around the world for the past five years, the deal locks up six months of marketing exclusivity in the all-important U.S. market. By law, the first generic drugmaker to enter the market faces no competition for 180 days, which means Ranbaxy could sell Lipitor at or near full price for half a year. Last year, Lipitor generated U.S. sales
...
|
| |
|
| Pfizer: 80mg Lipitor Dose Cuts Risk Of Cardiovascular Events |
| 2008-05-27 16:06:00 |
Pfizer Inc. (PFE) said an 80-milligram dose of Lipitor reduced the risk of major cardiovascular events, including heart attack and stroke, by 27% in patients with heart disease who had previous coronary bypass surgery compared with patients taking the 10-mg dose, according to a study.The New York pharmaceutical company said intensive Lipitor therapy also provided a 30% reduction in the need for either repeat coronary bypass surgery or angioplasty compared with the 10-mg dose, according to the study.
...
|
| |
|
| Pfizer's Lipitor Failed to Slow Alzheimer's Disease |
| 2008-04-20 06:10:00 |
Pfizer Inc.'s best-selling cholesterol drug Lipitor failed to slow mental and physical worsening in patients with Alzheimer's disease, a study found.The results clash with previous research that showed high cholesterol raises the risk of Alzheimer's disease, an inexorable loss of memory and function that affects 4.5 million Americans. The study of 640 patients, the largest ever on cholesterol-lowering statin drugs for the condition, found patients fared the same whether they got Lipitor or placebo.
...
|
| |
|
| Lipitor Shows Strong Anti-Ischemia Benefit |
| 2008-04-05 17:24:00 |
Pfizer Inc. (PFE) said Lipitor showed "unexpectedly potent" reduction in myocardial ischemia in its 80 milligram dose for patients with chronic chest pain.According to the company, the cholesterol drug reduced the occurrence of insufficient blood supply and oxygen to the heart by nearly 70% 18 weeks into a study. For 60% of patients, all ischemic events were completely eliminated by the end of the study.
...
|
| |
|
| Pfizer unleashes Asia strategy |
| 2008-03-18 16:30:00 |
Looking to decrease its dependence on single molecules, such as its $13 billion cholesterol drug Lipitor that is facing a generic onslaught, Pfizer has initiated business units to focus on oncology, biologics and even generics, he said. “We are depending on entrepreneurial parts of the company to make us successful. We are creating units and giving them the authority to be successful,” he said, adding: “It is better to be a patch-work quilt of success than a dinosaur!”On Pfizer’s dependence on Lipitor, he said that it was “too-distracting” to focus on a single molecule. “Last year, for the first time, we earned outside the US than inside,” he said.
...
|
| |
|
| Pfizer steels itself for Lipitor expiry |
| 2008-03-11 11:28:00 |
Pfizer sought to reassure investors yesterday that the unravelling of its "monolithic" structure would prepare it for the impending expiry of the patent for its blockbuster cholesterol drug Lipitor, worth some $12bn in annual sales.Under pressure from Wall Street to retool Pfizer to boost sales and profit, Jeff Kindler, chief executive, gave a frank assessment of the disruption created by its $90bn Warner-Lambert and $60bn Pharmacia deals since 2000. He provided the most detailed evidence yet of Pfizer's efforts to streamline its operations, change its culture and improve its research and science.
...
|
| |
|
| Lipitor Doctor |
| 2008-03-04 05:12:00 |
They have pulled all those ads that have been on television featuring Dr. Robert Jarvik, the inventor of the artificial heart, endorsing the product Lipitor for lowering your cholesterol. I have watched this commercial for several months and felt that it was suspicious because Jarvik was always referred to as "Doctor" and the word "physician" or "M.D," never came up.Then, in one commercial, he tells us he started studying architecture and changed because of his father's health. I never heard of a guy going from architecture to medicine. I wondered if he was some kind of Ph.D. they were trying to foist off as an M.D.
...
|
| |
|
| Lipitor vs. generics: which is for you? |
| 2008-02-28 05:14:00 |
"Lipitor is a highly effective drug, and it's one good choice for people who have high levels of LDL cholesterol, or who've had a heart attack, or who have acute coronary syndrome," said Williams. "However, the vast majority of people can get the same protection from a generic statin at less than half the cost."And although Lipitor's Web site makes a point of saying there is "no generic form of Lipitor," there will be in two years when its patent expires. No doubt that's another reason Pfizer is spending big bucks now to drill its brand name into your head.
...
|
| |
|
| Netherlands court stops Ranbaxy from launching Lipitor |
| 2008-02-23 08:58:00 |
An appellate court in the Netherlands has restrained India's largest drug firm Ranbaxy Laboratories Ltd from launching a generic version of cholesterol-lowering drug Lipitor in the country before November 2011.Ranbaxy has been trying to get US-based drug maker Pfizer's patent covering atorvastatin revoked in various countries which would make it possible for the Indian firm to launch a copy of the drug. Atorvastatin is the active ingredient in Lipitor, which has been patented by Pfizer globally.
...
|
| |
|
| Is Lipitor the Best Choice? |
| 2008-02-19 04:39:00 |
According to Consumer Reports, Lipitor is a highly effective drug and it’s one good choice for people who have high levels of LDL cholesterol, or who’ve had a heart attack, or who have acute coronary syndrome. However, the vast majority of people can get the same protection from a generic statin at less than half the cost.Generic drugs are chemical twins of brand-name drugs whose patents have expired. Three generic statins are now available: simvastatin, pravastatin, and lovastatin.
...
|
| |
|
| Health: Lipitor & Memory Loss |
| 2008-02-15 15:56:00 |
A growing number of patients say Lipitor is robbing their memories. Medical Reporter Stephanie Stahl has more on the drug's dark side.Maureen Webber had to quit her job. Her memory got so bad, she had to write down everything in a journal.
...
|
| |
|
| Lipitor TV Spots Raise Debate Over Advertising Practices |
| 2008-02-10 03:24:00 |
Lipitor is the top-selling drug in the world and Pfizer's biggest product, with $12.7 billion in sales last year. But it's been challenged in recent years by cheaper generic alternatives.Today, a front page New York Times story brought into the open a number of questions about the Jarvik ad and others in which prescription drugs are advertised directly to consumers.
...
|
| |
|
| Pfizer's Lipitor Down, Chantix Up in 2007 |
| 2008-02-03 17:50:00 |
Pharmaceutical revenue from Pfizer’s U.S. operations decreased last year as competition in the cholesterol market contributed to an 8 percent decline in revenues for the firm’s flagship product Lipitor. The company’s $48.6 billion 2007 total revenue was 1 percent better than its 2006 revenue of $48.4 billion.
...
|
| |
|
| Pfizer says Vytorin data give Lipitor more clout |
| 2008-01-28 00:44:00 |
Although Vytorin cut levels of "bad" LDL cholesterol far more than Merck's older Zocor tablet in the study, both drugs failed to prevent further buildup of fatty plaque in the carotid artery during the two-year study."It allows us to make our case the way we've been making it, and quite frankly gives it more teeth in terms of the clinical impact of our product," Pfizer Chief Financial Officer Frank D'Amelio told Reuters in an interview.
...
|
| |
|
| Jarvik Responds to Lipitor Ad Controversy |
| 2008-01-22 03:43:00 |
"I am a medical scientist not a practical physician," he said on "Good Morning America" today. "I think it's very upfront. I am a doctor. I have long experience with heart disease."Jarvik, who said he was aware of the drug and used it before he became its pitchman, said he believes the real issue isn't about him or his role in the ads.
...
|
| |
|
| Lipitor Shows Promise Vs Heart Attacks In Study |
| 2008-01-17 13:45:00 |
Pfizer Inc. (PFE) said a study showed that adding Lipitor tablets to early effective blood pressure treatment showed a 36% reduction in the relative risk of fatal or non-fatal heart attacks over five years.The New York pharmaceutical company said the results of the study were published online in the European Heart Journal.On Wednesday, Pfizer shares were up 10 cents, or 0.4%, to $23.69.
...
|
| |
|
| Pfizer says US Lipitor patent initially rejected |
| 2008-01-16 02:21:00 |
U.S. patent officials have initially rejected claims for the basic patent on Pfizer Inc's (PFE.N: Quote, Profile, Research) blockbuster Lipitor cholesterol treatment, although the drug maker said on Monday it remained confident the patent would ultimately be upheld.The patent, which expires in March 2010, will remain valid and enforceable while U.S. officials re-examine it, a process that could take as long as a few years, Pfizer said, allowing the company to maintain its grip on the product over that time.
...
|
| |
|
| Lipitor doesn't improve bone health after menopause |
| 2008-01-14 03:11:00 |
NEW YORK (Reuters Health) - When administered at doses that lower lipid levels, atorvastatin, sold in the U.S. under the trade name Lipitor, appears to have no effect on bone mineral density or bone metabolism in postmenopausal women, according to researchers.The results of previous laboratory and clinical studies have suggested the commonly prescribed class of cholesterol-lowering drugs called statins "may have very favorable effects on the skeleton," senior investigator Dr. Michael R. McClung told Reuters Health. "This study demonstrates clearly that statins do not have effects on bone in the clinical setting."
...
|
| |
|
| Study Finds Benefits of Pfizer's Lipitor |
| 2008-01-13 07:21:00 |
NEW YORK — Patients treated with Pfizer Inc.'s cholesterol drug Lipitor were significantly less likely to have a heart attack than those treated with generic Zocor, according to a Pfizer-funded study published Friday in Clinical Therapeutics Journal.New users of cholesterol-lowering drugs, without heart-related diseases, who took Lipitor (atorvastatin calcium) had a significantly lower relative risk of a heart attack compared with patients who took the generic, also known as simvastatin, according to the study results.
...
|
| |
|
| |
 |
